Biosynthetic human growth hormone in the treatment of growth hormone deficiency.

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Abstract Text:

J H Holcombe,P M Conforti,A C Wong,R G Thompson,M W Draper,

A total of 309 previously untreated children with growth hormone deficiency (GHD) (219 boys, 90 girls; mean age 8.4 +/- 3.9 years, range 1.5-19 years) were treated for up to 3 years in an ongoing trial designed to examine the long-term efficacy and safety of biosynthetic somatropin (rhGH). The children were treated with rhGH, 0.06 mg/kg (0.16 IU/kg) three times weekly. In the prepubertal children, the mean height velocity increased during the first year from 3.8 +/- 1.8 cm/year to 8.9 +/- 2.2 cm/year (n = 188). During the second and third years, their height velocities were 7.1 +/- 1.1 (n = 147) and 6.3 +/- 1.2 cm/year (n = 64), respectively. The height velocity SDS increased from -2.5 +/- 1.9 before treatment to 3.1 +/- 2.6 during the first year of treatment in the prepubertal children. The mean pretreatment height velocity in those with idiopathic GHD (3.8 +/- 1.6 cm/year) did not differ from that in children with organic GHD (3.8 +/- 2.3 cm/year). In addition, the height velocities during the first year of therapy did not differ significantly with respect to the aetiology of GHD. For the children who entered puberty during the study, the mean height velocity increased from 3.0 +/- 1.7 cm/year before treatment to 8.4 +/- 2.3 cm/year during the first year of rhGH therapy. In the first year, the height velocity of children with a bone age of less than 5 years (9.4 +/- 2.3 cm/year) was significantly greater than that in children with a bone age of 5-10 years (8.4 +/- 1.8 cm/year) or greater than 10 years (7.8 +/- 2.2 cm/year: p = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Publishing Authors By Initials

JH Holcombe,PM Conforti,AC Wong,RG Thompson,MW Draper,

For similar proteins: recombinant proteins research abstracts see: proteins: recombinant proteins research

PUBMED ID PMID:

MEDLINE DATE:

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Acta paediatrica Scandinavica. Supplement

VOLUME: 367

Page Numbers: 44-8

Journal Abbreviation:

ISSN: 0300-8843

DAY: 20

MONTH: 02

YEAR: 1990

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 173166

Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Keywords Mesh Terms:

KEYWORDS: Recombinant Proteins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Biosynthetic human growth hormone in the treatment of growth hormone deficiency. Information

Substance Name: Growth Hormone

Registry Number: 9002-72-6

Grant and Affiliation Information for Biosynthetic human growth hormone in the treatment of growth hormone deficiency.

AFFILIATION: Lilly Research Laboratories, Indianapolis.

Country: SWEDEN

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Acta Paediatr Scand Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Biosynthetic human growth hormone in the treatment of growth hormone deficiency Related Publications

• A review of the factors involved in older people's decision making with regard to influenza vaccination: a literature review.
• Biosynthetic human growth hormone in the treatment of growth hormone deficiency.
• Canadian Cancer Society.
• Cholera toxin up-regulates endoplasmic reticulum proteins that correlate with sensitivity to the toxin.
• Commentary on McGowan B (2006) 'Who do they think they are? Undergraduate perceptions of the definition of supernumerary status and how it works in practice'. Journal of Clinical Nursing 15, 1099-1105.
• Conducting cross-cultural research in teams and the search for the "culture-proof" variable.
• Depressive disorder associated with mycophenolate mofetil.
• Difficult IUD insertions.
• Economic policy--as if people mattered: towards health-promoting economic policy.
• Effect of E.R.A. on Local Programs.
• Effects of osmolytes on RNA secondary and tertiary structure stabilities and RNA-Mg2+ interactions.
• Importance of partially unfolded conformations for Mg(2+)-induced folding of RNA tertiary structure: structural models and free energies of Mg2+ interactions.
• Is sex-selective abortion morally justified and should it be prohibited?
• Mg2+-RNA interaction free energies and their relationship to the folding of RNA tertiary structures.
• Optical anisotropy of the human cornea determined with a polarizing microscope.
• PERINEPHRIC ABSCESS WITH GAS FORMATION.
• PERISTALSIS IN THE URINARY TRACT: EXPERIMENTAL OBSERVATIONS OF THE EFFECT OF VARIOUS DRUGS ON THE MUSCULATURE OF THE URETER.
• Paternity fraud and compensation for misattributed paternity.
• Preventing suicide minute by minute.
• Putting the pieces together.
• RURAL HEALTH WORK FROM THE NATIONAL VIEWPOINT.
• Regional load bearing of the canine acetabulum.
• Rhodium and palladium complexes of a pyridyl-centred polyphenylene derivative.
• Specific Interactions of the L10(L12)4 Ribosomal Protein Complex with mRNA, rRNA, and L11.
• State Support of Industrial Hygiene Services-An Urgent Necessity.
• Tertiary structure of an RNA pseudoknot is stabilized by "diffuse" Mg2+ ions.
• The essential concepts of nursing.
• The future of health promotion in Canada.
• The nutritional vulnerability of older Guyanese in residential homes.
• VIRGINIA PLAN OF COOPERATIVE COUNTY HEALTH WORK.